Evidence map›Paper›PMID 33336702›Full record

ArticleThe Journal of infectious diseases2021

Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network.

Jill M Ferdinands, Manjusha Gaglani, Shekhar Ghamande, Emily T Martin, Donald Middleton, Arnold S Monto, Fernanda Silveira, Helen K Talbot, Richard Zimmerman, Emily R Smith and 2 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jill M FerdinandsInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Manjusha GaglaniBaylor Scott & White Health System, Temple, Texas, USA.
Shekhar GhamandeBaylor Scott & White Health System, Temple, Texas, USA.
Emily T MartinUniversity of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Donald MiddletonUniversity of Pittsburgh Medical Center; Pittsburgh, Pennsylvania, USA.
Arnold S MontoUniversity of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Fernanda SilveiraUniversity of Pittsburgh Medical Center; Pittsburgh, Pennsylvania, USA.
Helen K TalbotVanderbilt University Medical Center, Nashville, Tennessee, USA.
Richard ZimmermanUniversity of Pittsburgh Medical Center; Pittsburgh, Pennsylvania, USA.
Emily R SmithInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Manish PatelInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) Study Investigators

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Flu vaccine effectiveness in thosehospitalized in a large diverse health systemU01IP000969 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2015 to 2019
$4.5M
US Hospital Vaccine Effectiveness (VE) Network - SupplementU01IP000974 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2015 to 2019
$4.5M
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient AdultsU01IP000972 · IP · SCOTT AND WHITE MEMORIAL HOSPITAL · PI GAGLANI, MANJUSHA · 2015 to 2019
$3.5M
NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR002243NCIRD CDC HHS U01 IP000969NCIRD CDC HHS U01 IP000972NCIRD CDC HHS U01 IP000974
6 · The paper itself

Abstract

We estimated vaccine effectiveness (VE) for prevention of influenza-associated hospitalizations among adults during the 2018-2019 influenza season. Adults admitted with acute respiratory illness to 14 hospitals of the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) and testing positive for influenza were cases; patients testing negative were controls. VE was estimated using logistic regression and inverse probability of treatment weighting. We analyzed data from 2863 patients with a mean age of 63 years. Adjusted VE against influenza A(H1N1)pdm09-associated hospitalization was 51% (95% confidence interval [CI], 25%-68%). Adjusted VE against influenza A(H3N2) virus-associated hospitalization was -2% (95% CI, -65% to 37%) and differed significantly by age, with VE of -130% (95% CI, -374% to -27%) among adults 18 to ≤56 years of age. Although vaccination halved the risk of influenza A(H1N1)pdm09-associated hospitalizations, it conferred no protection against influenza A(H3N2)-associated hospitalizations. We observed negative VE for young and middle-aged adults but cannot exclude residual confounding as a potential explanation.

Indexed as

HospitalizationVaccinationAdolescentAdultAgedAged, 80 and overFemaleHumansInfluenza VaccinesLogistic ModelsMaleMiddle AgedYoung AdultInfluenza Vaccinesadultscase-control studyhospitalizationinfluenzavaccinationvaccine effectiveness

Identifiers

PMID33336702
PMCPMC8427721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.